{
    "ticker": "VERU",
    "name": "Veru Inc.",
    "description": "Veru Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of prostate cancer and other urological diseases. Founded in 2016 and based in Miami, Florida, Veru is dedicated to addressing unmet medical needs through its proprietary products and clinical research. The company's lead product, VERU-111, is a novel investigational drug that is being evaluated for its efficacy in treating advanced prostate cancer, particularly in patients who have become resistant to standard hormone therapies. Veru also engages in the development of other therapeutic candidates aimed at treating sexual health disorders and breast cancer. The company is committed to conducting rigorous clinical trials to ensure the safety and efficacy of its products. With a focus on advancing scientific knowledge and improving patient outcomes, Veru strives to make a significant impact in oncology and urology through its innovative research and development efforts.",
    "industry": [
        "Biopharmaceuticals",
        "Oncology"
    ],
    "headquarters": "Miami, Florida, USA",
    "founded": "2016",
    "website": "https://www.verupharma.com",
    "ceo": "Dr. Mitchell Steiner",
    "social_media": {
        "twitter": "https://twitter.com/verupharm",
        "linkedin": "https://www.linkedin.com/company/veru-pharmaceuticals/"
    },
    "investor_relations": "https://ir.verupharma.com",
    "key_executives": [
        {
            "name": "Dr. Mitchell Steiner",
            "position": "CEO"
        },
        {
            "name": "Dr. Michael A. Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Products",
            "products": [
                "VERU-111"
            ]
        },
        {
            "category": "Sexual Health Products",
            "products": [
                "Tadalafil"
            ]
        }
    ],
    "seo": {
        "meta_title": "Veru Inc. | Biopharmaceutical Innovations in Oncology and Urology",
        "meta_description": "Explore Veru Inc., a biopharmaceutical company dedicated to developing innovative therapies for prostate cancer and urological disorders. Discover their leading products and commitment to patient care.",
        "keywords": [
            "Veru",
            "Biopharmaceuticals",
            "Prostate Cancer",
            "Oncology",
            "Urology",
            "VERU-111"
        ]
    },
    "faq": [
        {
            "question": "What is Veru known for?",
            "answer": "Veru is known for developing innovative medications for prostate cancer and urological diseases."
        },
        {
            "question": "Who is the CEO of Veru?",
            "answer": "Dr. Mitchell Steiner is the CEO of Veru Inc."
        },
        {
            "question": "Where is Veru headquartered?",
            "answer": "Veru is headquartered in Miami, Florida, USA."
        },
        {
            "question": "What are Veru's main products?",
            "answer": "Veru's main products include VERU-111 and Tadalafil."
        },
        {
            "question": "When was Veru founded?",
            "answer": "Veru was founded in 2016."
        }
    ],
    "competitors": [
        "EXEL",
        "CLVS",
        "MDGL",
        "BLUE"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "ABBV",
        "REGN"
    ]
}